Psychopharmacological Aspects of Geriatric Medicine

  • H. E. Lehmann
Part of the Advances in Behavioral Biology book series (ABBI, volume 3)


Geriatric patients frequently develop psychiatric disorders, so frequently, in fact, that a new subspecialty of geriatric medicine has recently emerged which is becoming known as geropsychiatry. The psychiatric syndromes and symptoms observed in geriatric patients are not essentially different from those encountered in younger patients, but aging tends to develop certain “host qualities” in people which render them selectively more susceptible to certain stresses and more prone to certain pathological manifestations than to others. Because aging favors degenerative diseases, we see in geriatric patients a prevalence of psychopathology which is either the direct outcome of degenerative brain disease or reflects a functional reaction to it.


Geriatric Patient Geriatric Medicine Delirium Tremens Organic Brain Syndrome Critical Flicker Fusion Frequency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmed, A. 1968. Thioridazine in the management of geriatric patients. J. Amer. Geriat. 16(8):945.Google Scholar
  2. Altschul, R. 1959. Einfluss von Cytochrome C auf Serum Cholesterin. Kreislaufforsch. 48:844.Google Scholar
  3. Asian, A. 1956. A new method for prophylaxis and treatment of aging with novocain-eutrophic and rejuvenating effects. Therapiewoche 7:14.Google Scholar
  4. Assessment in Cerebrovascular Insufficiency. An International Symposium on Various Methods of Assessing the Effects of Cyclandelate on Higher Cortical Function, Würzburg 1970. G. Stöker, R.A. Kuhn, P. Hall, G. Becker, E. van der Veen (eds.). Stuttgart:Georg Thieme Verlag, 1971.Google Scholar
  5. Bergener, von M. 1967. Behandlung psychiatrischer Krankheitszustände in Alter. Hippokrates 38:432.PubMedGoogle Scholar
  6. Bogomolets, A.P. 1946. The Prolongation of Life. New York:Duell, Sloan & Pearce.Google Scholar
  7. Bower, H.M., and McDonald, C. 1966. A controlled trial of A.N.P. 235 (“Lucidrir”) in senile dementia. Med. J. Aust. 2(6):270.PubMedGoogle Scholar
  8. Burke, G., and Halko, A. 1968. Quoted in editorial by W.C. Alvarez. Geriatrics 23:96.Google Scholar
  9. Chynoweth, R., and Foley, J. 1969. Pre-senile dementia responding to steroid therapy. Brit. J. Psychiat. 115:703.PubMedCrossRefGoogle Scholar
  10. Deitrick, R.A. 1967. Pentylenetetrazol with nicotinic acid in the management of chronic brain syndrome. J. Amer. Geriat. 15:191.Google Scholar
  11. Espie, M.J. 1966. Pharmacologie de la centrophénoxine. Application au delirium tremens. Lyon Med. 215:935.Google Scholar
  12. Fünfgeld, E.W. 1970. Ergebnisse medikamentöser Therapie bei älteren Patienten mit cerebralorganischen Störungen. Nervenarzt 41:352.PubMedGoogle Scholar
  13. Gerstenbrand, F.; Hoff, H.; and Prosenz, P. 1963. Therapeutische Erfahrungen mit Lucidril bei neuro-psychiatrischen Krankheitsbildern. (Therapeutic experiences with Lucidril in neuropsychiatric disease pictures.) Wien. Med. Wschr. 113(25–26):539.PubMedGoogle Scholar
  14. Hall, P. and Harcup, M. 1969 suppl. A trial of lipotropic enzymes in atheromatous (“arteriosclerotic”) dementia. Angiology 20:287.PubMedCrossRefGoogle Scholar
  15. Hedlund, S.; Köhler, V.; Nylin, G.P.; Olsson, R.; Regnström, O.; Rothström, E.; and Aström, K.E. 1964. Cerebral blood circulation in dementia. Acta Psychiat. Scand. 40:77.PubMedCrossRefGoogle Scholar
  16. Hunter, J.D. 1960. Nicotinic acid therapy in patients with coronary disease. New Zeal MJ. 59:60. Kayatan, S. 1960. Atherosclerosis and betaglucuronidase. Lancet 2:667.Google Scholar
  17. Kety, S.S. 1956. Human cerebral blood flow oxygen consumption as related to aging. In The Neurologic and Psychiatric Aspects of the Disorders of Aging. Baltimore: Williams & Wilkins.Google Scholar
  18. Kral, V.A. 1958. Senescent memory decline and senile amnestic syndrome. Amer. J. Psychiat. 115:361.PubMedGoogle Scholar
  19. LaBrecque, D.C., and Goldberg, R.I. 1967. A double blind study of pentylenetetrazol combined with niacin in senile patients. Curr. Ther. Res. 9:611.PubMedGoogle Scholar
  20. Leckman, J.; Ananth, J.V.; Ban, T.A.; and Lehmann, H.E. 1971. Pentylenetetrazol in the treatment of geriatric patients with disturbed memory function. J. Clin. Pharmacol. 11(4):301.Google Scholar
  21. Lehmann, H.E. 1959. Methods of evaluation of drug effects on the human central nervous system. In The Effect of Pharmacologic Agents on the Nervous System. Baltimore: Williams & Wilkins.Google Scholar
  22. Lehmann, H.E., and Ban, T.A. 1970. Pharmacological load tests as predictors of pharmacotherapeutic response in geriatric patients. In Psychopharmacology and the Individual Patient. J.R. Wittenborn, S.G. Goldberg, and P.R.A. May (eds.). New York: Raven Press.Google Scholar
  23. Lehmann, H.E.; Ban, T.A.; and Kral, V.A. 1968. Psychological tests: Practice effect in geriatric patients. Geriatrics 23:160.PubMedGoogle Scholar
  24. Lehmann, H.E., and Knight, D.A. 1958. Psychophysiological testing with a new phrenotropic drug. In Trifluoperazine: Clinical and Pharmacological Aspects. H. Brill (ed.). Philadelphia:Lea & Febiger.Google Scholar
  25. Levy, S. 1963. Pharmacological treatment of aged patients in a state mental hospital. JAMA 153:1260.CrossRefGoogle Scholar
  26. Lifschitz, K., and Kline, N. 1963. Psychopharmacology of the aged. In Clinical Principles and Drugs in the Aging. J. Freeman (ed.). Springfield: Charles C Thomas.Google Scholar
  27. Müller, H. 1967. Drugs — EEG and the aged. Presented at a symposium on Psychoactive Drugs in the Aged. Quebec Psychopharmacological Research Association, Quebec, Canada.Google Scholar
  28. Niehans, P. 1952. Zur Geschichte der Zellular-Therapie, zugleich eine Richtigstellung. Hippokrates 27:219.Google Scholar
  29. Overall J.E., and Gorham D.R. Feb. 1971. Organicity versus old age in objective and projective test. performance. Psychometric Laboratory Reports No. 16. Dept. of Neurology and Psychiatry, Psychometric Laboratory. The University of Texas Medical Branch, Galveston, Texas.Google Scholar
  30. Schindler, Von R.; Steininger, E.; and Waitusch, A. 1968. Noverilbehandlung von psychiatrischen Alterpatienten. Wien. Med. Wschr. 118:368.PubMedGoogle Scholar
  31. Silver, D.; Debow, S.L.; Lehmann, H.E.; Kral, V.A.; and Ban, T.A. Nov. 1967. The comparative effectiveness of psychoactive drugs in hospitalized geriatric patients. Presented at the Quebec Psychopharmacological Research Association Meeting, Quebec, Canada.Google Scholar
  32. Stern, F.H. 1970. Management of chronic brain syndrome secondary to cerebral arteriosclerosis, with special reference to papaverine hydrochloride. J. Amer. Geriat. 18(6):507.Google Scholar
  33. Stöker, G. 1971. Cerebral functions and cerebral blood flow. In Assessment in Cerebrovascular Insufficiency by G. Stöker, R.A. Kuhn, P. Hall, G. Becker, and E. van der Veen. Stuttgart: Georg Thieme Verlag.Google Scholar
  34. Wietec, H.F. 1966. Zum Einfluss von Centrophenoxin auf das Alterspigment Lipofuscin in Nervenzellen. (The influence of centrophenoxine on lipofuscin, the pigment of old age in nerve cells). Arzneimittel-Forschung 16(8): 1123.Google Scholar

Copyright information

© Plenum Press, New York 1972

Authors and Affiliations

  • H. E. Lehmann
    • 1
  1. 1.Douglas HospitalVerdunCanada

Personalised recommendations